Novartis (VTX:NOVN) has been assigned a CHF 82 price target by stock analysts at JPMorgan Chase & Co. in a report issued on Wednesday, Borsen Zeitung reports. The brokerage presently has a “sell” rating on the stock.
A number of other equities research analysts have also weighed in on the stock. Barclays set a CHF 80 price objective on shares of Novartis and gave the company a “sell” rating in a report on Thursday, September 5th. Bank of America set a CHF 104 target price on shares of Novartis and gave the company a “buy” rating in a research report on Tuesday. Morgan Stanley set a CHF 84 target price on shares of Novartis and gave the company a “sell” rating in a research report on Monday. HSBC set a CHF 88 target price on shares of Novartis and gave the company a “neutral” rating in a research report on Monday, July 22nd. Finally, Credit Suisse Group set a CHF 88 target price on shares of Novartis and gave the company a “neutral” rating in a research report on Friday, July 19th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. Novartis currently has an average rating of “Hold” and a consensus price target of CHF 90.82.
Novartis has a twelve month low of CHF 72.45 and a twelve month high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
See Also: Bull Market
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.